カワチ薬品's consolidated ordinary profit for the first half fell 8.9% year on year to ¥3.46 billion, while ordinary profit for the most recent July–September quarter also dropped approximately 20% year on year to ¥1.75 billion.
カワチ薬品 reported consolidated ordinary profit of ¥3.46 billion for the cumulative second quarter (April–September) of the fiscal year ending March 2027, a year-on-year decline of 8.9%. Progress against the full-year plan was 57.8%, almost in line with the five-year average of 55.3%.
Ordinary profit for the July–September quarter, the latest three-month period, was ¥1.75 billion, down 19.9% year on year. The operating margin on sales deteriorated from 2.6% to 2.2%.
For the outlook, consolidated ordinary profit for the October–March period, the second half, is estimated at ¥2.53 billion, representing an expected decline of 38.1% from the same period a year earlier.